+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of estrogen dependency of human breast cancers 2. clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer



Evaluation of estrogen dependency of human breast cancers 2. clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer



Hiroshima Journal of Medical Sciences 33(2): 163-166



An antiestrogen (tamoxifen) was given to 17 patients with advanced breast cancer (both recurrent and primary cancers) during a period from June 1981 to Sept. 1983. The response rate to the antiestrogen was 47.8% (8/17). Sixty percent (6/10) of patients with estrogen receptor positive (ER+) responded, compared with 16.7% (1/6) of patients with estrogen receptor negative (ER-). Of patients with soft tissue/lymph nodes involvement, 40% responded, compared with 27.2% in patients with bone metastasis, and 25.0% in patients with visceral involvement. Postmenopausal patients responded more than premenopausal ones. In recurrent cases, the response rate increased with the prolongation of disease free interval. Eight out of 17 patients are still alive, and the longest survival case has been in a condition of partial response for 23 mo. so far. The mean survival period in 9 deaths was 13 .+-. 9 mo., with longest 32 mo. As shown here, some patients with advanced breast cancer respond very well to the therapy. Tamoxifen-containing endocrinotherapy in combination with chemotherapy apparently is effective in treatment of advanced cancer and its active application may enable patients to live longer.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005398147

Download citation: RISBibTeXText

PMID: 6480380


Related references

Evaluation of estrogen dependency of human breast cancers 1. cytochemical study of estrogen receptor in human breast cancer tissue. Hiroshima Journal of Medical Sciences 33(2): 157-162, 1984

Clinical evaluation of tamoxifen for advanced and recurrent breast cancer. Horumon to Rinsho. Clinical Endocrinology 28(4): 425-436, 1980

Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(2): 247-258, 1993

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology 8(8): 1679-1689, 2014

Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(12): 1949-1956, 1994

Histological and clinical response evaluation to primary chemotherapy in local-advanced breast cancers. European Journal of Cancer 32A(Suppl. 1): S21, 1996

Tamoxifen therapy in locally advanced primary and recurrent breast cancer. Nihon Gan Chiryo Gakkai Shi 14(5): 819-824, 1979

Estrogen-regulated proteins in human breast cancer Clinical value in advanced breast cancer and correlation with estrogen receptor. Wegmann, R J , Wegmann, M A Recent Advances in Cellular and Molecular Biology, Vol 4 ; Molecular pathways of kinases, protein expression, blood pressure regulators, Ca-2 channels and molecular receptors : 243-251, 1992

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. Journal of Clinical Oncology 26(22): 3727-3734, 2008

Clinical evaluation of estrogen-androgen combination in advanced breast cancer. American Journal of Surgery 117(4): 589-594, 1969

Results of comparative clinical evaluation of the antiestrogens toremifene and tamoxifen in locally advanced and disseminated breast cancer. Voprosy Onkologii (St Petersburg) 36(10): 1182-1186, 1990

Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(6): 1863-1871, 1988

Clinical evaluation of adriamycin ointment in advanced or local recurrent breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(3 Pt 1): 590-592, 1986

Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 467-475, 1995

Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(4): 477-484, 1994